Compositions and methods for cancer diagnosis and treatment

Details Compositions and methods for cancer diagnosis and treatment Compositions and methods for cancer diagnosis and treatment

2006-05-02

2011-12-06

McGarry, Sean (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024100, C536S024500

Reexamination Certificate

active

08071559

ABSTRACT:
The application relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the mir17-92 cluster. The application further relates to screening methods to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.

REFERENCES:
patent: 5093246 (1992-03-01), Cech et al.
patent: 7232806 (2007-06-01), Tuschl et al.
patent: 7759319 (2010-07-01), Lollo et al.
patent: 2005/0186205 (2005-08-01), Anderson et al.
patent: 2005/0261218 (2005-11-01), Esau et al.
patent: 2008/0268453 (2008-10-01), Seto et al.
patent: WO03/029459 (2003-04-01), None
patent: WO2005/078139 (2005-08-01), None
Peracchi, A. et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Chirila, T. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Branch, A. Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Crooke, S., Antisense Research & Application, Chapter 1, pp. 1-50. Ed. by S. Crooke, Springer-Verlag, Publ. (1998).
Opalinska et al, Nature Rev., vol. 1, pp. 503-514 (2002).
Ota et al., Cancer Research, vol. 64, pp. 3087-3095 (2004).
Cheng et al., 2005, Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis, Nucleic Acids Res. 33(4):1290-1297.
Couzin, 2002, Breakthrough of the year. Small RNAs make big splash, Science 298(5602):2296-7.
Dennis, 2002, Small RNAs: the genome's guiding hand? Nature 420(6917):732.
Griffiths-Jones, 2004, The microRNA Registry, Nucleic Acids Res. 32:D109-D111.
He and Hannon, 2004, MicroRNAs: Small RNAs with a big role in gene regulation, Nature 5:522-531.
He et al., 2005, A microRNA polycistron as a potential human oncogene, Nature 435(9):828-833.
Hutvágner et al., 2004, Sequence-Specific Inhibition of Small RNA Function, PloS Biology 2(4):465-475.
Kidner and Martienssen, 2003, Macro effects of microRNAs in plants, Trends Genet. 19(1):13-6.
Meister et al., 2004, Sequence-Specific inhibition of microRNA- and siRNA-induced RNA silencing, RNA Journal 10:544-550.
Zeng and Cullen, 2003, Sequence requirements for micro RNA processing and function in human cells, RNA 9(1):112-123.
Eis et al., 2005, Accumulation of miR-155 andBICRNA in human B cell lymphomas, Proc. Natl. Acad. Sci. USA 102(10)3627-3632.
Lagos-Quintana et al., 2001, Identification of Novel Genes Coding for Small Expressed RNAs, Science 294:853-858.
Mourelatos et al., 2002, miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs, Genes & Dev. 16:720-728.
Ota et al., 2004, Identification and Characterization of a Novel Gene,CI3orf25, as a Target for 13q31-q32 Amplification in Malignant Lymphoma, Cancer Res. 64:3087-3095.
Bartel et al., “MicroRNA: Genomics, Biogenesis, Mechanism, and function,” Cell, vol. 116, pp. 281-297 (Jan. 23, 2004).
Czech et al., “MicroRNAs as therapeutic targets,” The new England Journal of Medicine, vol. 354, pp. 1194-1195 (Mar. 16, 2006).
Elmen et al., “LNA-mediated microRNA silencing in non-human primates,” Nature, vol. 452, pp. 896-900, (Apr. 17, 2008).
Esau et al., “miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting,” Cell metabolism, vol. 3, pp. 87-98 (Feb. 2006).
Fluiter et al., “In vivo tumor growth inhibition and bio distribution studies of locked nucleic acid (LNA) antisense oligonucleotides,” Nucleic Acids Research, vol. 31, pp. 953-962 (2003).
Krutzfeldt et al., Silencing of microRNAs in vivo with ‘antagomirs,’ Nature Letters, vol. 438, pp. 685-689, (2005).
Michael et al., “Reduced Accumulation of Specific MicroRNAs in colorectal Neoplasia,” Molecular Cancer Research, vol. 1, pp. 882-891 (Oct. 2003).
Morrissey et al., “Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs,” Nature biotechnology, vol. 23, pp. 1002-1007 (Aug. 2005).
Obad et al., “Silencing of microRNA families by seed-targeting tiny LNAs. Supplementary Information” Nature Genetics, vol. 43. pp. 1-20 (2011).
Obad et al., “Silencing of microRNA families by seed-targeting tiny LNAs.” Nature Genetics, vol. 43. pp. 371-378 (2011).
Soutschek et al., “Therapeutic silencing of an endogenous gene by Systemic administration of modified siRNAs,” Nature, vol. 432, pp. 173-178 (Nov. 2004).
Zimmermann et asl., “RNAi-mediated gene silencing in non-human primates”,Nature, vol. 441, pp. 111-114, (May 4, 2006).

Affiliated with

Also associated with

Rating

Compositions and methods for cancer diagnosis and treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for cancer diagnosis and treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for cancer diagnosis and treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4313961